Skip to content

Advertisement

  • Primary research
  • Open Access

Tumor-associated macrophages derived CCL18 promotes metastasis in squamous cell carcinoma of the head and neck

Cancer Cell International201818:120

https://doi.org/10.1186/s12935-018-0620-1

  • Received: 18 January 2018
  • Accepted: 14 August 2018
  • Published:

Abstract

Background

Alternatively activated macrophages in tumor microenvironment is defined as M2 tumor-associated macrophages (M2 TAMs) that promote cancer progression. However, communicative mechanisms between M2 TAMs and cancer cells in squamous cell carcinoma of head and neck (SCCHN) remain largely unknown.

Methods

Quantitative real-time PCR, western blotting, enzyme-linked immunosorbent assay and flow cytometry were applied to quantify mRNA and protein expression of genes related to M2 TAMs, epithelial–mesenchymal transition (EMT) and stemness. Wounding-healing and Transwell invasion assays were performed to detect the invasion and migration. Sphere formation assay was used to detect the stemness of SCCHN cells. RNA-sequencing and following bioinformatics analysis were used to determine the alterations of transcriptome.

Results

THP-1 monocytes were successfully polarized into M2-like TAMs, which was manifested by increased mRNA and protein expression of CCL18, IL-10 and CD206. Conditioned medium from M2-like TAMs promoted the migration and invasion of SCCHN cells, which was accompanied by the occurrence of EMT and enhanced stemness. Importantly, CCL18 neutralizing antibody partially abrogated these effects that caused by conditional medium from M2-like TAMs. In addition, recombinant human CCL18 (rhCCL18) correspondingly promoted the malignant biological behaviors of SCCHN in vitro. Finally, RNA-sequencing analysis identified 331 up-regulated and 363 down-regulated genes stimulated by rhCCL18, which were statistically enriched in 10 cancer associated signaling pathways.

Conclusion

These findings indicate that CCL18 derived from M2-like TAMs promotes metastasis via inducing EMT and cancer stemness in SCCHN in vitro.

Keywords

  • Squamous cell carcinoma of head and neck
  • Tumor-associated macrophage
  • CCL18
  • Metastasis
  • Epithelial–mesenchymal transition
  • Stemness

Background

Squamous cell carcinoma of head and neck (SCCHN) originates from the nasal cavities, paranasal sinuses, oral cavity, nasopharynx, oropharynx, hypopharynx and larynx. It ranks as the sixth aggressive malignancy in the world. Although multiple therapies including surgery, radiotherapy and chemotherapy have been applied in clinical settings for decades, the prognosis of SCCHN patients are still unsatisfactory [1]. Lymph node metastasis is one of major causes for a poor prognosis in SCCHN patients [2, 3]. Therefore, it is urgent and imperative to clarify the mechanisms underlying metastasis, which will benefit future surveillance and target therapy for SCCHN patients.

Tumor microenvironment (TME) is composed by diverse cell types including cancer cells, immune cells and multiple molecules such as cytokines, chemokines and metabolites etc. [4, 5]. Communications between cancer cells and stromal cells is important in cancer malignant transformation and progression [6]. Peripheral monocytes infiltrate into tumors, are educated by TME and polarize into classically activated type 1 (M1) macrophages or alternatively activated type 2 (M2) macrophages. Tumor-associated macrophages (TAMs) include M1 and M2 TAMs, M2 TAMs always facilitate angiogenesis, matrix breakdown and cancer cell movement, all of which are indispensable elements for cancer metastasis [7, 8]. Therefore, macrophages represent a valuable therapeutic target for cancer [911]. Importantly, clinical data from patient samples indicate that macrophage infiltration is negatively correlated with the poor prognosis in diverse cancers [1216].

Cancer cells and TAMs have their own specific and/or common secretions and metabolites, which together reprogram each side. For example, TAMs can provide pleiotrophin for glioblastoma to maintain stemness and promote malignant growth [17]. Cancer cells secrete VEGF or CCL2 to recruit monocyte to tumors [18, 19]. In another aspect, cancer cells and TAMs compete essential nutrition for survival, and lactic acid produced by cancer cells also induces polarization of M2 TAMs [20]. However, signals involved in the mutual communication between TAMs and cancer cells are complex and poorly understood.

Chemokine (C-C motif) ligand 18 (CCL18), a member of CC chemokine family, is predominantly produced by M2 TAMs [21]. CCL18 overexpression is observed in breast cancer [12], ovarian cancer [22], and glioma [23] etc., which predicts a poor prognosis. In vitro and in vivo experiments indicate that M2 TAMs-derived CCL18 promotes the metastasis in breast carcinoma [12] and pancreatic ductal adenocarcinoma [15]. However, the effects of CCL18 in SCCHN are poorly unknown [24]. In this study, we confirmed the crosstalk between TAMs and SCCHN cells. Moreover, TAMs derived CCL18 promoted the migration and invasion via inducing epithelial–mesenchymal transition (EMT) and maintaining stemness of SCCHN in vitro.

Materials and methods

Cell cultures, treatment and conditional medium collection

SCCHN Tu686 cell line, established from a primary tongue tumor, was kindly provided by Dr. Zhuo Chen (Emory University Winship Cancer Institute, Atlanta, Georgia, USA). SCCHN FaDu cell line, established from a hypopharyngeal tumor removed from a Hindu patient, was purchased American Type Culture Collection (ATCC, VA, USA). Human THP-1 monocytes were obtained from American Type Culture Collection (ATCC, VA, USA). Tu686 cells were cultured in DMEM/F12 medium, FaDu cells were cultured in DMEM medium and THP-1 cells were maintained in RPMI 1640 medium at 37 °C in 5% CO2 atmosphere, which containing 10% foetal bovine serum (FBS, Gibco), 100 IU/mL penicillin and 100 μg/mL streptomycin (Gibco).

THP-1 cells were differentiated into M0 macrophages by incubation with 200 ng/mL phorbol 12-myristate 13-acetate (PMA, Sigma, MO, USA) in serum-free medium for 24 h. Then, M0 macrophages were polarized in M2-like TAMs by incubation with 20 ng/mL of recombinant human interleukin 4 protein (rhIL-4, R&D Systems Inc., MN, USA) and 20 ng/mL of recombinant human interleukin 13 protein (rhIL-13, R&D Systems Inc., MN, USA) for another 24 h [25]. The supernatants from M2-like TAMs and M0 macrophages were filtered and defined as M2-like TAMs conditioned medium (CM) and M0 CM, which were used by the addition of 30% fresh complete medium in the following experiments. Tu686 and FaDu cells were incubated with recombinant human CCL18 (rhCCL18) protein (Abnova, CA, USA) at the concentration of 20 ng/mL for 48 h and then subjected to the following experiments.

Quantitative reverse transcription-polymerase chain reaction analysis (qRT-PCR)

Total RNA was isolated from cells (Tu686, FaDu or monocyte/macrophages) using TRIzol reagent (Invitrogen, CA, USA) according to the manufacturer’s instructions. To quantify the expressions of mRNAs, High Capacity RNA-to-cDNA kit and SYBR® Green PCR Master Mix (Applied Biosystems, CA, USA) were used for reverse transcription and PCR amplification. GAPDH was used as an endogenous control. The expression levels were quantified using the methods of 2−∆∆Ct [26]. All primer sequences were listed in Table 1. Each experiment was performed in triplicate.
Table 1

qPCR primers used in this paper

qPCR primers

Genes

Primer-forward

Primer-reverse

CD206

CAG GTG TGG GCT CAG GTA GT

TGT GGT GAG CTG AAA GGT GA

CCL18

CTC TGC TGC CTC GTC TAT ACC T

CTT GGT TAG GAG GAT GAC ACC T

IL-10

GGT TGC CAA GCC TTG TCT GA

AGG GAG TTC ACA TGC GCC T

CCL22

ATG GCT CGC CTA CAG ACT GCA CTC

CAC GGC AGC AGA CGC TGT CTT CCA

CD133

CAG AGT ACA ACG CCA AAC CA

AAA TCA CGA TGA GGG TCA GC

CD44

TGC CGC TTT GCA GGT GTA T

GGC CTC CGT CCG AGA GA

ALDH1

TCC TGG TTA TGG GCC TAC AG

CTG GCC CTG GTG GTA GAA TA

E-cadherin

GCT GGA CCG AGA GAG TTT CC

CAA AAT CCA AGC CCG TGG TG

Vimentin

TGT CCA AAT CGA TGT GGA TGT TTC

TTG TAC CAT TCT TCT GCC TCC TG

Snail

CCT CCC TGT CAG ATG AGG AC

CCA GGC TGA GGT ATT CCT TG

Slug

GCT CAG AAA GCC CCA TTA GTG ATG

GCC AGC CCA GAA AAA GTT GAA TAG

GAPDH

TCC AAA ATC AAG TGG GGC GA

AGT AGA GGC AGG GAT GAT GT

Flow cytometry analysis

To evaluate the expression of surface proteins on macrophages including CD206 and CD163, polarized and nonpolarized macrophages were collected and resuspended in cold PBS containing 2% BSA (Sigma, MO, USA), then incubated with FITC mouse anti-human CD206 (BD Biosciences, CA, USA) and PE mouse anti-human CD163 (BioLegend, CA, USA) on ice for 30 min. To further confirm the stemness of SCCHN cells, Tu686 cells were dissociated into single-cell suspension and resuspended in cold PBS containing 2% BSA (Sigma, MO, USA), then stained with PE-Cy5 anti-human CD133 antibody (BioLegend, CA, USA) and FITC mouse anti-human CD44 antibody (BioLegend, CA, USA) on ice for 1 h. Cells were analyzed by flow cytometry with a FACS Calibur instrument (BD Biosciences, CA, USA). All data was analyzed using FlowJo software (Tree Star Inc., OR, USA). The experiments were performed in twice.

Enzyme-linked immunosorbent assay (ELISA)

Cytokine levels of CCL18 and IL-10 in supernatants of M0 or M2-like macrophages were determined by a human CCL18/PARC ELISA kit (R&D Systems Inc., MN, USA) and human IL-10 ELISA kit (R&D Systems Inc., MN, USA) according to manufacturer’s instructions. Each experiment was performed in triplicate.

Wounding-healing and Transwell invasion assay

The wound-healing and invasion assays have been described previously [2729]. The experiments were performed in triplicate. For wound-healing assay, Tu686 and FaDu cells were seeded into 6-well plates and grown to 80–90% confluence. Then, the cells were disrupted with a standard 10 μL sterile micropipette tip and washed with PBS, which were exposed to different conditioned medium for 48 h. Photographs were captured under phase-contrast microscope.

For Transwell invasion assay, transwell chambers with polycarbonate filter were used, which were coated with Matrigel (Corning, NY, USA) at a concentration of 200 μg/mL. Tu686 or FaDu cells were plated in the upper 24-well Transwell chambers with serum-free medium. Meanwhile, conditioned medium was applied to the lower chamber as chemoattractant for 48 h. After removing the cells on the upper surface of the membrane, 4% formaldehyde and hematoxylin and eosin (HE) were used to fix and stain the cells, respectively. Invaded cells were counted and photographed under a microscope.

Western blotting

Whole cell protein extracts were collected and western blot assays were performed as we previously described [27, 28]. 30–50 μg total protein extracts were separated by 8–12% SDS-PAGE and then transferred onto polyvinylidene difluoride membrane (Millipore, MA, USA). The blotted membranes were incubated with primary antibodies and subsequently incubated with an HRP-labeled secondary antibody. β-actin (1:2000; Beyotime, China) was used as a loading control. All antibodies in our study are listed as followed: N-cadherin (1:1200; Proteintech Group Inc., IL, USA); E-cadherin (1:1200; Proteintech Group Inc., IL, USA); Vimentin (1:1200; Proteintech Group Inc., IL, USA); Snail (1:500; Santa Cruz, TX, USA); Slug (1:500; Santa Cruz, TX, USA); HRP-anti-mouse or anti-rabbit IgGs (1:2000; Beyotime, China). Each experiment was performed in triplicate.

Sphere culture and formation assay

For tumorsphere formation assay, Tu686 cells were cultured as a monolayer before being harvested as single cell suspension. Cells were suspended in tumorsphere medium (serum-free DMEM/F-12 medium supplemented with 20 ng/mL human recombinant epidermal growth factor (EGF; Millipore, MA, USA), 20 ng/mL human recombinant basic fibroblast growth factor (bFGF; PeproTech, NJ, USA) and 2% B27), and then subsequently plated in ultra-low attachment 24-well plates (Corning, NY, USA) at a density of no more than 2000 cells/well. Sphere formation was allowed for 10–14 days [30, 31]. The experiments were performed in triplicate.

RNA-sequencing analysis

Total RNA from Tu686 cells with or without rhCCL18 stimulation was extracted and quantified, library preparation and sequencing. The libraries were sequenced on the Illumina Hiseq 4000 platform. Reads containing adapter or poly-N and reads of low quality were removed from raw data to generate clean reads. Based on the clean reads, Q20, Q30, and GC content of the clean data were calculated. Next, mapped reads were obtained through aligning clean reads to the human genome reference (hg19) by TopHat v2.0.9. To determine expression level of each unigenes, the number of mapped clean reads was counted and normalized into reads per kb per million reads (RPKM).

GO and KEGG enrichment analysis

Gene Ontology (GO) enrichment analysis of differentially expressed genes were implemented by the GOseq R package, in which gene length bias was corrected. GO terms with corrected P < 0.05 were considered significantly enriched by differential expressed genes. Kyoto Encyclopedia of Genes and Genomes (KEGG) is a database resource for understanding high-level functions and utilities of the biological system, such as the cell, the organism and the ecosystem, from molecular-level information, especially large-scale molecular datasets generated by genome sequencing and other high-throughput experimental technologies (http://www.genome.jp/kegg/). We used KOBAS software to test the statistical enrichment of differential expression genes (DEGs) in KEGG pathways.

Statistical analysis

All data were evaluated using IBM SPSS version 13.0. Unpaired t test or one-way ANOVA test was performed to analyze the significant differences between groups. The quantitative data in this study were expressed as the mean ± standard deviation (SD). Differences were considered statistically significant at the value of P < 0.05.

Results

In vitro polarization of THP-1 cells into M2-like TAMs

Monocytes can be induced into M2-like TAMs via combinational stimulation with PMA, rhIL-4 and rhIL-13 in vitro [25, 32, 33]. Hence, we used this protocol to polarize THP-1 monocytes. M2-like TAMs is characterized by high expression of scavenging receptor CD163, mannose receptor CD206 and increased secretion of cytokines such as IL-10, CCL18 and CCL22 etc. Upon 24 h stimulation, qPCR data clearly showed that cytokine mRNAs including IL-10, CCL18 and CCL22 were dramatically increased (Fig. 1a). ELISA assays further confirmed that IL-10 and CCL18 proteins were correspondingly elevated in the culture medium from polarized macrophages (Fig. 1c). FACS analyses revealed that expression of M2 macrophage membrane receptors including CD163 and CD206 was increased (Fig. 1b). These data indicate that THP-1 monocytes are successfully polarized into M2-like TAMs in vitro.
Fig. 1
Fig. 1

In vitro polarization of THP-1 cells into M2-like TAMs. THP-1 monocytes were treated with the combination of PMA, rhIL-4 and rhIL-13. a mRNA expression of M2 macrophages markers (CD206, CCL18, IL-10 and CCL18) was quantified by qRT-PCR. b Cell surface proteins of CD206 and CD163 were analyzed by flow cytometry. c CCL18 and IL-10 secretion in culture medium was measured by ELISA. Results are shown as mean ± SD. **P <0.01, ***P < 0.001, ****P < 0.0001

M2-like TAMs promote migration and invasion of SCCHN cells in vitro

To confirm potential communications between M2-like TAMs and SCCHN cells, conditional medium (CM) from unpolarized (M0 CM) and polarized M2-like TAMs (M2 CM) were collected and used in the following experiments. Our data clearly showed that wound-healing ability of Tu686 cells cultured with M2 CM significantly enhanced at 48 h compared with cells treated with M0 CM (Fig. 2a, b). Consistent with wound healing results, Transwell chamber assays revealed that M2 CM promoted the invasive capacity of Tu686 cells (Fig. 2c, d). In addition, M2 CM treatment showed only mild but not statistically different influence on the cell proliferation in vitro. These data indicate that M2-like TAMs enhance the migration and invasion of SCCHN cells in vitro.
Fig. 2
Fig. 2

M2-like TAMs promote migration and invasion of SCCHN in vitro. Tu686 cells cultured with M2 CM or M0 CM for 2 days. Wounding-healing assays (a, b) and Transwell chamber assays (c, d) were used to measure the changes in migration and invasion of Tu686 cells. Data are shown as mean ± SD. **P <0.01, ****P < 0.0001

M2-like TAMs induce EMT and stemness in SCCHN in vitro

Epithelial–mesenchymal transition (EMT) is tightly associated with cancer metastasis, which is characterized by canonical morphological and molecular alterations [28, 29]. Upon M2 CM treatment for 3 days, morphology of Tu686 cells transformed to a fibroblast-like shape with less cell–cell contact (Fig. 3a). Moreover, M2 CM induced gradual downregulation of epithelial marker E-cadherin and upregulation of mesenchymal markers N-cadherin and Vimentin at protein level (Fig. 3b, c). Snail and Slug are two critical transcription factors for EMT. M2 CM also significantly increased the expression of Snail and Slug at protein level in Tu686 cells (Fig. 3d, e).
Fig. 3
Fig. 3

M2-like TAMs induce EMT and stemness in SCCHN in vitro. Tu686 cells cultured with M2 CM or M0 CM for 2 days. a Representative morphological images (original magnification 100×). b, c EMT proteins were examined and semi-quantified by western blotting. Similar with b and c, proteins (d and e) of EMT transcription factors Slug and Snail were also measured. f, g Images of tumorspheres and their quantification were shown. h mRNA expression of CSCs markers CD133, CCL44 and ALDH1 was quantified by qPCR. i Proteins of CD133 or/and CD44 were analyzed by flow cytometry. Results are shown as mean ± SD. *P < 0.05, **P <0.01, ***P < 0.001, ****P < 0.0001

Increasing evidence has demonstrated that cancer cells undergoing EMT changes always increase their stemness [31]. Therefore, we examined the effects of M2 CM on SCCHN stemness. Sphere formation assays revealed that M2 CM treatment generated more and larger tumorspheres in Tu686 cells in vitro (Fig. 3f, g), indicating that M2 CM enhanced SCCHN stemness. Correspondingly, qPCR data showed that M2 CM significantly increased mRNA expression of SCCHN stem markers including CD133, CD44 and ALDH1 (Fig. 3h). FACS analysis further confirmed that M2 CM increased the proportions of CD133+, CD44+ and CD133+CD44+ Tu686 cells (Fig. 3i). Taken together, the above data clearly reveal that M2-like TAMs boost EMT and enhance stemness of SCCHN cells, which in turn leads to phenotype changes associated with SCCHN metastasis.

CCL18 participates in M2-like TAMs mediated metastasis of SCCHN in vitro

CCL18, as one of the most important cytokines secreted by M2 TAMs, functions critically in cancer metastasis. As showed in Fig. 1c, CCL18 secretion was drastically elevated in polarized M2-like TAMs. To confirm whether CCL18 directly functioned in M2-like TAMs mediated SCCHN metastasis, specific neutralizing antibody was used to block the binding between CCL18 and its receptor. As anticipated, CCL18 neutralizing antibody at the concentration of 15 μg/mL successfully impeded the migration (Fig. 4a, b) and invasion (Fig. 4c, d) of Tu686 cells enhanced by M2 CM. However, IgG isotype recombinant protein had no reversal effects (Fig. 4a, d). Although CCL18 neutralizing antibody only partially reversed the effects of M2 CM (Fig. 4a, d), these data still demonstrate that CCL18 contributes to enhanced metastasis that induced by M2-like TAMs.
Fig. 4
Fig. 4

CCL18 participates in M2-like TAMs mediated metastasis of SCCHN in vitro. Tu686 cells cultured with M2 CM or M0 CM in the presence or absence of an anti-CCL18 neutralizing antibody at 15 μg/mL, or an isotype-matched IgG protein. Wounding-healing assays (a, b) and Transwell chamber assays (c, d) were used to measure the changes in migration and invasion of Tu686 cells. Data are shown as mean ± SD. **P <0.01, ****P < 0.0001

CCL18 involves in M2-like TAMs induced EMT and stemness in SCCHN in vitro

We also investigated whether CCL18 neutralizing antibody could reverse EMT and stemness mediated by M2 CM. qPCR data indicated that neutralizing antibody completely restored mRNA expression of epithelial marker E-cadherin, partially inhibited the elevation of mesenchymal marker Vimentin, Snail and Slug (Fig. 5a, d). Meantime, size of tumorsphere became smaller and number decreased after the addition of neutralizing antibody (Fig. 5e, f), which was accompanied by declined mRNA expression of stem cell genes including CD133 and CD44 (Fig. 5g, h). All these results suggest that M2-like TAMs-derived CCL18 promotes changes of phenotype associated with SCCHN metastasis via inducing EMT and stemness.
Fig. 5
Fig. 5

CCL18 involves in M2-like TAMs induced EMT and stemness in SCCHN in vitro. Tu686 cells cultured with M2 CM or M0 CM in the presence or absence of an anti-CCL18 neutralizing antibody at 15 μg/mL, or an isotype-matched IgG protein. ad qRT-PCR assays were used to check mRNA expression of EMT markers E-cadherin (a), Vimentin (b), and EMT transcription factors Snail (c) and Slug (d). e, f Representative images for tumorsphere formation and the number of tumorspheres. g, h mRNA expression of CSCs markers CD133 (g) and CD44 (h) was quantified by qPCR. Data are shown as mean ± SD. *P < 0.05, **P <0.01, ***P < 0.001, ****P < 0.0001

CCL18-mediated effects on FaDu cells

To further strengthen the reliability of our conclusion and to exclude the possibility that the effect of CCL18 on SCCHN was Tu686 cell specific, another SCCHN FaDu cell line was used. As expected, rhCCL18 stimulation obviously enhanced the wound healing (Fig. 6a, b) and invasive ability (Fig. 6c, d) of FaDu cells in vitro. Accordingly, rhCCL18 treatment declined the expression of E-cadherin and increased the expression of Vimentin at both transcriptional and translational levels (Fig. 6e, f). In addition, mRNA expression of CSCs markers CD133 and ALDH1 was also upregulated when exposed to rhCCL18 (Fig. 6g). These findings in FaDu cells are consistent with that in Tu686 cells, which consolidates the conclusion that CCL18 promotes metastasis-associated phenotypes via the induction of EMT and stemness in SCCHN.
Fig. 6
Fig. 6

CCL18 mediated effects on FaDu cells. SCCHN FaDu cells were treated by rhCCL18 for 3 days and then subjected to the following assays. a, b Migratory changes were examined by wound healing assays and quantified. c, d Invasive ability was assayed by Transwell chamber assays and quantified. e, f mRNA and proteins associated with EMT were leveled by qPCR and western blotting assays. g mRNAs of CSCs markers CD133 and ALDH1 were quantified by qPCR. **P <0.01, ***P < 0.001, ****P < 0.0001

Identification of CCL18-regulated genes and pathways

To better understand the underlying molecular mechanism, Tu686 cells treated with or without rhCCL18 for 3 days were subjected to RNA-sequencing. With the cutoff criteria of an absolute fold-change ≥ 2.0 and P < 0.05, a total of 694 genes were differentially expressed, in which 331 genes were increased and 363 genes were declined with CCL18 stimulation (Fig. 7a and Additional file 1). In addition, GO biological process, molecular function and cellular component for the 694 DEGs were also analyzed (Fig. 7b and Additional file 2). KEGG pathway analysis revealed that 10 pathways were significant enriched after rhCCL18 stimulation (P < 0.05), which included colorectal cancer and RIG-1-like receptor signaling pathway etc. (Fig. 7c and Additional file 3). The colorectal cancer pathway, as the most significant pathway, contained 12 DEGs (Fig. 7d and Additional file 3).
Fig. 7
Fig. 7

Identification of CCL18-regulated genes and signaling pathways in SCCHN cells. a Volcano plot representing the RNA-sequencing results. Red dots indicated up-regulated genes induced by rhCCL18; blue dots were down-regulated genes at a cutoff criteria of fold change ≥ 2.0 and P < 0.05. b Go analysis including the biological process, molecular function and cellular component were performed on the 694 DEGs. c The top 10 signaling pathways analyzed by the KEGG signaling pathway enrichment analysis. d KEGG pathway map of the colorectal cancer pathway with DEGs indicated

Discussion

M2 TAMs, one of the inflammatory immune cells in tumor microenvironment, functions importantly in cancer initiation and progression [3436]. In our current study, monocyte THP-1 was polarized into M2-like TAMs via the combination stimulation with PMA, IL-4 and IL-13. M2-like TAMs significantly promoted the migration and invasion of SCCHN cells in vitro, which was tightly associated with EMT and stemness. More importantly, we found that CCL18 in M2-like TAMs induced EMT and stemness and then led to SCCHN metastasis. Taken together, our current demonstrated that CCL18 derived from M2-like TAMs may drove SCCHN metastasis via inducing EMT and stemness.

M2 TAMs secret diverse cytokines, enzymes and chemokines, which are involved in cancer malignant progression. CCL16, IL-10, Arginase 1, YM1, VEGF and CCL18 are routine secretions from M2 TAMs under different circumstances [37]. In the secretory profile, VEGF is a well-known pro-angiogenesis protein that facilitates cancer metastasis [38]. IL-10 is a pleiotropic cytokine that is important in inflammation-induced carcinogenesis [39]. Arginase 1 metabolizes l-arginine and participates in the remodeling of T cell functions and tissue repair [40]. These secretions form a complicated network that connects TAMs, tumor cells and other stroma cells in TME. The mutual interactions reprogram each cell type in TME and evolve together with cancer progression. In our current study, M2-like TAMs CM induces EMT, sustains cancer stemness and drastically enhances the capacity of migration and invasion of SCCHN cells, which reveals that specific secretory alteration after M2 polarization of macrophages may contribute to SCCHN metastasis. These data are consistent with previous investigations in other solid tumors [12, 15, 17].

CCL18 is mainly produced by M2 TAMs, which has been reported to promote cancer metastasis via binding to its receptor Nir1 (also named PITPNM3) in multiple human malignancies including breast carcinoma [12], hepatocellular carcinoma [41], ovarian cancer [42], nasopharyngeal carcinoma [43] and lung cancer [44] etc. Therefore, we used neutralizing antibody to block the binding of CCL18 to its receptor Nir1. As anticipated, neutralizing antibody successfully impedes the migration, invasion and markers of EMT and stemness in SCCHN cells in vitro. These data indicate that CCL18 produced by M2 TAMs contributes to the phenotypes associated with metastasis in SCCHN.

However, we have to mention that CCL18 neutralizing antibody only partially inhibits the function of M2-like TAMs, which means that other mechanisms are also involved in mutual communication between TAMs and cancer cells. The phenomenon can be logically explained by the following reasons. Firstly, our current study only focus on cytokine CCL18, it is reasonable to assume that other secretory proteins may also tightly associated with M2 TAMs mediated cancer progression. Secondly, nutrition competition and cell metabolites such as lactic acid and fumarate etc., are critical and indispensable components of CM, which have been intensively investigated and reported to function in cancer progression [20, 45]. Thirdly, the cell–cell communications also exist among other cell types. For instance, M2 TAMs display high expression of PD-L1 that accelerates the exhaustion of tumor infiltrating lymphocytes such as CD8 T cells, leads to suppressive antitumor immunity and cancer progression [46].

CCL18 exerts its function via binding to the receptor Nir1 on cancer cell surface and then activates downstream signaling pathways, which include the mammalian target of rapamycin (mTOR) [47], NF-κB [41] and PI3K/Akt signaling pathways [48] etc. We have found that activation of CCL18/Nir1 signaling pathway can increase the expression of oncogene MTDH, which is important for the promotion of SCCHN metastasis in our previous studies (Data are prepared in another manuscript) [27, 28, 49]. In addition, high throughput sequencing techniques are also employed in our lab to systematically and thoroughly explore the potential downstream signaling components of CCL18/Nir1. Our RNA-sequencing analysis indicates that rhCCL18 induces a transcriptome change that includes 331 up-regulated and 363 down-regulated genes. To thoroughly investigate the molecular mechanism of CCL18, KEGG analysis further demonstrate that 10 signaling pathways are enriched by these 694 DEGs. In these enriched pathways, colorectal cancer signaling pathway, ranking in the first place, includes 12 DEGs caused by CCL18 stimulation, which is involved in cancer initiation and progression. Among other pathways, RIG-I-like receptors signaling pathway is tightly associated with antiviral immunity and inflammatory response [50]. Other pathways did not seem to be directly associated with cancer at first glance. This can be explained by the notion that KEGG analyses are based on available published online data and that these genes involved in the enriched pathways are annotated not only to cancer, but also to many other diseases or biological functions.

Conclusion

Taken together, our study suggests that M2 TAMs produce CCL18 to induce EMT and cancer stemness, which in turn leads to SCCHN metastasis. However, in-depth molecular mechanism investigation and further in vivo animal models are required to further strengthen our current conclusion.

Abbreviations

TAMs: 

tumor-associated macrophages

TME: 

tumor microenvironment

CCL18: 

Chemokine (C-C motif) ligand 18

EMT: 

epithelial–mesenchymal transition

SCCHN: 

squamous cell carcinoma of the head and neck

DEGs: 

differential expression genes

Declarations

Authors’ contributions

YL, DHH and XZ conceived and designed the study. LS performed all experiments and wrote the manuscript. YXQ, JCW, CL, GCZ, GL, MW, CHC, GCL, DKZ, XYC and YYW assisted with experimental performance. YZQ, YQT and DHH assisted with the data analysis. LS, XZ and YL modified the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets used and/or analyzed in the present study are available from the manuscript.

Consent for publication

All authors consent for publication.

Ethics approval and consent to participate

Not applicable.

Funding

This study was funded by grants from the National Natural Science Foundation of China (Nos. 81874133,  81772903, 81773243, 81602389, 81602684, 81472696 and 81372426); the National Key Research and Development Program of China (No. 2016YFC0902003); the Natural Science Foundation of Hunan Province (Nos. 2018JJ2630, 2017JJ3456 and 2017JJ3488); the Hunan Provincial Innovation Foundation for Postgraduate (No. CX2017B068); the Huxiang Young Talent Project for Yong Liu and the Xiangya Hospital-Sinobioway Clinic and Rehabilitation Research Foundation (No. xywm2015123).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, People’s Republic of China
(2)
Otolaryngology Major Disease Research Key Laboratory of Hunan Province, 87 Xiangya Road, Changsha, 410008, Hunan, People’s Republic of China
(3)
Department of Otolaryngology Head and Neck Surgery, The Second Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410010, Hunan, People’s Republic of China

References

  1. Allen CT, Law JH, Dunn GP, Uppaluri R. Emerging insights into head and neck cancer metastasis. Head Neck. 2013;35(11):1669–78.View ArticlePubMedGoogle Scholar
  2. Elsheikh MN, Rinaldo A, Hamakawa H, Mahfouz ME, Rodrigo JP, Brennan J, Devaney KO, Grandis JR, Ferlito A. Importance of molecular analysis in detecting cervical lymph node metastasis in head and neck squamous cell carcinoma. Head Neck. 2006;28(9):842–9.View ArticlePubMedGoogle Scholar
  3. Cai GM, Huang DH, Dai YZ, Liu Y, Pi LM, Tan HL, Liu LJ, Lv YX, Yu CY, Tan PQ, et al. Analysis of transcriptional factors and regulation networks in laryngeal squamous cell carcinoma patients with lymph node metastasis. J Proteome Res. 2012;11(2):1100–7.View ArticlePubMedGoogle Scholar
  4. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49–61.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Robinson BD, Sica GL, Liu YF, Rohan TE, Gertler FB, Condeelis JS, Jones JG. Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res. 2009;15(7):2433–41.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Kaminska K, Szczylik C, Bielecka ZF, Bartnik E, Porta C, Lian F, Czarnecka AM. The role of the cell–cell interactions in cancer progression. J Cell Mol Med. 2015;19(2):283–96.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood. 2006;107(5):2112–22.View ArticlePubMedGoogle Scholar
  8. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–55.View ArticlePubMedGoogle Scholar
  9. Gordon S. The macrophage: past, present and future. Eur J Immunol. 2007;37(Suppl 1):S9–17.View ArticlePubMedGoogle Scholar
  10. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953–64.View ArticlePubMedGoogle Scholar
  11. Ostuni R, Kratochvill F, Murray PJ, Natoli G. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol. 2015;36(4):229–39.View ArticlePubMedGoogle Scholar
  12. Chen J, Yao Y, Gong C, Yu F, Su S, Chen J, Liu B, Deng H, Wang F, Lin L, et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell. 2011;19(4):541–55.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda DG, et al. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncology. 2013;15(8):1079–87.View ArticlePubMedPubMed CentralGoogle Scholar
  14. He KF, Zhang L, Huang CF, Ma SR, Wang YF, Wang WM, Zhao ZL, Liu B, Zhao YF, Zhang WF, et al. CD163+ tumor-associated macrophages correlated with poor prognosis and cancer stem cells in oral squamous cell carcinoma. Biomed Res Int. 2014;2014:838632.PubMedPubMed CentralGoogle Scholar
  15. Meng F, Li W, Li C, Gao Z, Guo K, Song S. CCL18 promotes epithelial–mesenchymal transition, invasion and migration of pancreatic cancer cells in pancreatic ductal adenocarcinoma. Int J Oncol. 2015;46(3):1109–20.View ArticlePubMedGoogle Scholar
  16. Hu Y, He MY, Zhu LF, Yang CC, Zhou ML, Wang Q, Zhang W, Zheng YY, Wang DM, Xu ZQ, et al. Tumor-associated macrophages correlate with the clinicopathological features and poor outcomes via inducing epithelial to mesenchymal transition in oral squamous cell carcinoma. J Exp Clin Cancer Res. 2016;35:12.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Shi Y, Ping YF, Zhou W, He ZC, Chen C, Bian BS, Zhang L, Chen L, Lan X, Zhang XC, et al. Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth. Nat Commun. 2017;8:15080.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Barbera-Guillem E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res. 2002;62(23):7042–9.PubMedGoogle Scholar
  19. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222–5.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC, Phillips GM, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513(7519):559–63.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Schraufstatter IU, Zhao M, Khaldoyanidi SK, Discipio RG. The chemokine CCL18 causes maturation of cultured monocytes to macrophages in the M2 spectrum. Immunology. 2012;135(4):287–98.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B, Peperstraete L, Van de Putte I, Saccani A, Allavena P, et al. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem. 2002;277(27):24584–93.View ArticlePubMedGoogle Scholar
  23. Chang CY, Lee YH, Leu SJ, Wang CY, Wei CP, Hung KS, Pai MH, Tsai MD, Wu CH. CC-chemokine ligand 18/pulmonary activation-regulated chemokine expression in the CNS with special reference to traumatic brain injuries and neoplastic disorders. Neuroscience. 2010;165(4):1233–43.View ArticlePubMedGoogle Scholar
  24. Wang H, Liang X, Li M, Tao X, Tai S, Fan Z, Wang Z, Cheng B, Xia J. Chemokine (CC motif) ligand 18 upregulates Slug expression to promote stem-cell like features by activating the mammalian target of rapamycin pathway in oral squamous cell carcinoma. Cancer Sci. 2017;108(8):1584–93.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Genin M, Clement F, Fattaccioli A, Raes M, Michiels C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer. 2015;15:577.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–8.View ArticlePubMedGoogle Scholar
  27. Zhu GC, Yu CY, She L, Tan HL, Li G, Ren SL, Su ZW, Wei M, Huang DH, Tian YQ, et al. Metadherin regulation of vascular endothelial growth factor expression is dependent upon the PI3K/Akt pathway in squamous cell carcinoma of the head and neck. Medicine. 2015;94(6):e502.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Yu C, Liu Y, Tan H, Li G, Su Z, Ren S, Zhu G, Tian Y, Qiu Y, Zhang X. Metadherin regulates metastasis of squamous cell carcinoma of the head and neck via AKT signalling pathway-mediated epithelial–mesenchymal transition. Cancer Lett. 2014;343(2):258–67.View ArticlePubMedGoogle Scholar
  29. Liu Y, Yu C, Qiu Y, Huang D, Zhou X, Zhang X, Tian Y. Downregulation of EphA2 expression suppresses the growth and metastasis in squamous-cell carcinoma of the head and neck in vitro and in vivo. J Cancer Res Clin Oncol. 2012;138(2):195–202.View ArticlePubMedGoogle Scholar
  30. Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell. 2011;8(5):486–98.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Cao L, Zhou Y, Zhai B, Liao J, Xu W, Zhang R, Li J, Zhang Y, Chen L, Qian H, et al. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol. 2011;11:71.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177(10):7303–11.View ArticlePubMedGoogle Scholar
  33. Smith MP, Sanchez-Laorden B, O’Brien K, Brunton H, Ferguson J, Young H, Dhomen N, Flaherty KT, Frederick DT, Cooper ZA, et al. The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha. Cancer Discov. 2014;4(10):1214–29.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4(1):71–8.View ArticlePubMedGoogle Scholar
  35. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124(2):263–6.View ArticlePubMedGoogle Scholar
  36. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22(2):231–7.View ArticlePubMedGoogle Scholar
  37. Roszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm. 2015;2015:816460.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2011;2(12):1097–105.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Monticelli LA, Buck MD, Flamar AL, Saenz SA, Wojno EDT, Yudanin NA, Osborne LC, Hepworth MR, Tran SV, Rodewald HR, et al. Arginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation. Nat Immunol. 2016;17(6):656–65.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Lin Z, Li W, Zhang H, Wu W, Peng Y, Zeng Y, Wan Y, Wang J, Ouyang N. CCL18/PITPNM3 enhances migration, invasion, and EMT through the NF-kappaB signaling pathway in hepatocellular carcinoma. Tumour Biol. 2016;37(3):3461–8.View ArticlePubMedGoogle Scholar
  42. Lane D, Matte I, Laplante C, Garde-Granger P, Carignan A, Bessette P, Rancourt C, Piche A. CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling. Mol Cancer. 2016;15(1):58.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Huang D, Song SJ, Wu ZZ, Wu W, Cui XY, Chen JN, Zeng MS, Su SC. Epstein–Barr virus-induced VEGF and GM-CSF drive nasopharyngeal carcinoma metastasis via recruitment and activation of macrophages. Cancer Res. 2017;77(13):3591–604.View ArticlePubMedGoogle Scholar
  44. Shi L, Zhang B, Sun X, Zhang X, Lv S, Li H, Wang X, Zhao C, Zhang H, Xie X, et al. CC chemokine ligand 18(CCL18) promotes migration and invasion of lung cancer cells by binding to Nir1 through Nir1-ELMO1/DOC180 signaling pathway. Mol Carcinog. 2016;55(12):2051–62.View ArticlePubMedGoogle Scholar
  45. Sciacovelli M, Goncalves E, Johnson TI, Zecchini VR, da Costa AS, Gaude E, Drubbel AV, Theobald SJ, Abbo SR, Tran MG, et al. Corrigendum: fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature. 2016;540(7631):150.View ArticlePubMedGoogle Scholar
  46. Prima V, Kaliberova LN, Kaliberov S, Curiel DT, Kusmartsev S. COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proc Natl Acad Sci USA. 2017;114(5):1117–22.View ArticlePubMedGoogle Scholar
  47. Wang Q, Tang Y, Yu H, Yin Q, Li M, Shi L, Zhang W, Li D, Li L. CCL18 from tumor-cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway. Mol Carcinog. 2016;55(11):1688–99.View ArticlePubMedGoogle Scholar
  48. Zhang B, Yin C, Li H, Shi L, Liu N, Sun Y, Lu S, Liu Y, Sun L, Li X, et al. Nir1 promotes invasion of breast cancer cells by binding to chemokine (C-C motif) ligand 18 through the PI3K/Akt/GSK3beta/Snail signalling pathway. Eur J Cancer. 2013;49(18):3900–13.View ArticlePubMedGoogle Scholar
  49. She L, Tan HL, Zhu GC, Wei M, Chen CH, Pi LM, Liu GC, Zhang DK, Huang DH, Zhang X, et al. MiR-98 regulates the malignant progression of nasopharyngeal carcinoma via targeting MTDH. Chin J Otorhinolaryngol Skull Base Surg. 2016;22(6):455–611.Google Scholar
  50. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2018

Advertisement